An update of advanced nanoplatforms for Glioblastoma Multiforme Management
Glioblastoma multiforme (GBM) is a very aggressive and heterogeneous glioma. Currently, GBM is treated with a combination of surgery, radiotherapy, chemotherapy (e.g. temozolamide) and Tumour Treating Fields. Unfortunately, the mean survival is still around 15 months. This poor prognosis is associa...
Main Authors: | , , , , , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
IfADo - Leibniz Research Centre for Working Environment and Human Factors, Dortmund
2021-11-01
|
Series: | EXCLI Journal : Experimental and Clinical Sciences |
Subjects: | |
Online Access: | https://www.excli.de/index.php/excli/article/view/4393 |